E.g., 04/19/2024
E.g., 04/19/2024
Title Category Credit Event date Pricesort ascending
PARPi: Genetic Testing in Advanced Prostate Cancer - When and Who to Test Webcast (2023)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The American Urological Association (AUA) has developed a series of live virtual and on-demand educational offerings to further address the identified educational gaps and barriers in advanced prostate cancer care. Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessments, a three-part educational series to update urologists and advanced practice providers (APPs) on PARP-inhibitor (PARPi) treatment in advanced prostate cancer is being offered.
Prostate Cancer Diagnosis: AUA Guidelines on Use of PSA Biomarkers, MRI and Biopsy Techniques Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Prostate cancer detection remains one of the most common and most controversial aspects of urological practice. In addition to the complexities around screening and use of PSA, the role of other biomarkers, biopsy techniques such as transperineal biopsy and MRI for targeted biopsy are evolving rapidly. This course is intended for urologists, advanced practice providers and trainees interested in using the most evidence-based methods for optimizing detection of clinically important prostate cancers, while improving patient experience and minimizing complications.
PARPi: Management of Adverse Events Webcast (2024)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The American Urological Association (AUA) has developed a series of live virtual and on-demand educational offerings to further address the identified educational gaps and barriers in advanced prostate cancer care. Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessments, a three-part educational series to update urologists and advanced practice providers (APPs) on PARP-inhibitor (PARPi) treatment in advanced prostate cancer is being offered.
Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Review of advanced and metastatic prostate, bladder and kidney cancer. Most recent treatment guidelines are reviewed along with the studies that support them. Different disease spaces in oncologic care are discussed, including the medications used to treat them, their mechanism, side effects and efficacy. Role of the advanced practice provider is discussed for each tumor type. Finally, cases are presented along with management options for audience participationACKNOWLEDGEMENTSIndependent educational grant support provided by:
How to use PSMA-PET/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 he learners will understand the following critical clinical aspects with regard to the clinical application of prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)/CT scanning mode of action of PSMA-PET/CT: pitfalls of PSMA-PET/CT diagnostic accuracy depending on PSA, PSA double time, prostate cancer histology, application of PSMA-PET/CT to identify patients with intrapelvic nodal relapse who will benefit from local therapy such as salvage lymphadenectomy or stereotactic radiation therapy, application of PSMA-PET/CT to identify patients with organ-confined radiorecur
Genetics and Genomics of GU Malignancies: Applications into Your Clinical Practice Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This case-based interactive course reviews the role of germline genetics in genitourinary (GU) cancers and how the identification of an alteration may impact precision oncology. We will provide a concise and comprehensive review of hereditary cancer genetics, and discuss genetic risk assessment, diagnosis and treatment for a range of hereditary kidney, urothelial carcinoma, prostate, and adrenal cancer syndromes. We will review current National Comprehensive Cancer Network® Guidelines for genetic evaluation of patients with kidney, upper tract, prostate, and adrenal cancers.
Managing Toxicities of Checkpoint Inhibitors: A Urologist’s Guide Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Checkpoint inhibitors (CPIs) are increasingly being utilized in the treatment of urinary tract cancers, with several approvals in metastatic and now nonmetastatic spaces in bladder, kidney and prostate cancer. Urologists are encountering many patients on these therapies and have even started their own infusion programs with immuno -oncology drugs. This course will discuss and provide a structured, case-based approach to managing toxicities from CPIs within a busy urological practice.
Building a Primary Palliative Care Model for Urology Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Building a Primary Palliative Care Model for Urology Webcast (2021) discusses aspects of palliative care that benefit patients, the urologist’s role and their collaboration with palliative care clinicians including:
Upper-Tract Urothelial Cancer Guidelines: An Interactive and Evidence-based Course Highlighting the Full Spectrum of Disease via Case Discussion and...
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This course will walk through the newly developed AUA Guidelines for Upper Tract Urothelial Cancer (UTUC) using an interactive discussion of complex cases with attendee involvement to enhance their knowledge of this challenging disease and provide a basis for practice improvement. Aspects such as optimizing initial workup and risk stratification, endoscopic techniques for biopsy and treatment, multidisciplinary management (e.g., coordinating with medical oncology, nephrology, genetic counseling) and nuances of surgical approaches will be stressed.
Diversity, Equity and Inclusion in Urology: What Do We Need to Know Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 The course will review the statistics of underrepresented Blacks and Latinos in urology. Diversity, equity and inclusion initiatives are necessary for the advancement of urology. We will also include the LGBTQ population with respect to diversifying the urology workforce and identifying specific patient needs for the LGBTQ population. We will define the different types of racism and educate participants on the definition of racial and gender-based microaggression. We will identify tactics to address microaggressions in medicine.
Advancing Gender Equity in Urology: Allyship for Men and Advocacy for Women Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 There is a lack of widespread awareness of how gender bias or sexism affects women in the urological workplace, and while primarily women are contributing to the scientific literature that examines these issues, its dissemination to those in leadership or in charge of policy can be limited. Addressing this requires both advocacy from women and allyship from men to promote fair and equitable work environments.
What the General Urologist Should Know about Care of Transgender Patients Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Transgender individuals are becoming more prevalent in society. There are an estimated 1,400,000 individuals in the U.S. with gender dysphoria. Many of these patients will undergo medical and surgical transformation. Transgender patients at various stages of their transformation will present to urological clinics for care. It is important for urologists to understand the transition process and the unique components of caring for transgender patients.
Global Advancements in Bladder Cancer Webcast (2023)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00
The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion Webcast (2023)
    • 4.25 AMA PRA Category 1 Credit™
    • 4.25 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. The course will discuss the importance of developing a multidisciplinary approach and key components to establishing a multidisciplinary clinic.
Treatment for Hormone Sensitive Prostate Cancer Webcast (2023)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00

Pages